林业发展局批准Symves,这是一艘新的生物工程血液容器,以防止在动脉损伤中丧失肢体。 FDA approves Symvess, a new bioengineered blood vessel to prevent limb loss in arterial injuries.

林业发展局批准了Symves,这是一艘新的生物工程血管,用于紧急动脉损伤,以防止肢体丧失。 The FDA has approved Symvess, a new bioengineered blood vessel designed for urgent cases of arterial injury to prevent limb loss. 该船由Humacyte Global开发,由人类外细胞基质蛋白制成,在对54名病人进行的一项研究中显示出效果。 Developed by Humacyte Global, this vessel is made from human extracellular matrix proteins and has shown effectiveness in a study with 54 patients. 与合成移植相比,Symves对感染有更好的抵抗力,并可能减少在严重血管损伤中截肢的需要。 Compared to synthetic grafts, Symvess offers better resistance to infection and may reduce the need for amputations in severe vascular injuries.